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FACTORS ASSOCIATED WITH SUBOPTIMAL ADHERENCE TO HUMAN 
IMMUNODEFICIENCY VIRUS THERAPY
Snower KN, Lynn JB
CVS Caremark, Northbrook, IL, USA
OBJECTIVES: Adherence to medications is an integral component of treating human 
immunodeﬁciency virus (HIV). The objective of this study was to identify factors 
associated with suboptimal adherence to HIV therapy (MPR < 95%). METHODS: 
HIV patients were identiﬁed by a pharmacy claim between January 1, 2008 and 
November 30, 2008, for a non-nucleoside reverse transcriptase inhibitor, protease 
inhibitor, nucleoside reverse transcriptase inhibitor, entry inhibitor, integrase inhibitor 
or combination medication, using a large de-identiﬁed administrative claims database. 
Medication possession ratio (MPR) was calculated during the 12 months following 
their index prescription for those patients continuously enrolled and with at least two 
ﬁlls per medication. For patients utilizing more than one HIV medication, a mean 
MPR was calculated, weighted by length of time on each medication. Logistic regres-
sion was used to identify factors associated with suboptimal adherence. RESULTS: 
The analysis included 18,497 patients (20.0% female, mean age 46.7 years). Mean 
MPR was 87.2% (95% CI: 86.9–87.4), with 48.6% of patients having suboptimal 
adherence. Suboptimal adherence was associated with female gender (OR = 1.55, 95% 
CI: 1.44–1.68), dispenses from retail pharmacies (OR = 1.54, 95% CI: 1.43–1.67), 
less than three-months supply per dispense (OR = 1.38, 95% CI: 1.26–1.52), patient 
age less than 45 years (OR = 1.26, 95% CI: 1.18–1.34), using more than one pharmacy 
for HIV medications (OR = 1.20, 95% CI: 1.11–1.29), being new to therapy (OR = 
1.12, 95% CI: 1.04–1.19), taking more pills per day (OR = 1.09 for each additional 
pill per day, 95% CI: 1.06–1.12) and using more HIV medications (OR = 1.08 for 
each additional medication, 95% CI: 1.06–1.11). Type of insurance coverage and 
amount of copay were not signiﬁcantly associated with suboptimal adherence. CON-
CLUSIONS: Knowledge of factors related to suboptimal adherence can help identify 
HIV patients who may require additional attention during their course of care.
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FEASIBILITY STUDY OF A NOVEL METHOD TO QUANTIFY SURGICAL 
INTERVENTIONS IN PATIENTS WITH COMPLICATED SKIN AND SKIN 
STRUCTURE INFECTIONS (CSSSI) USING HOSPITAL ELECTRONIC 
HEALTH RECORD DATA
Emons MF1, Campbell RS1, Kothari S2, Fiske S1, Hays HD1, Zilberberg M3
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Astellas Pharma US, Deerﬁeld, IL, USA, 
3University of Massachusetts, Goshen, MA, USA
OBJECTIVES: cSSSI may be associated with signiﬁcant morbidity and cost. ICD-
9-CM diagnosis codes have been used to identify cSSSI in health care databases. 
Although early surgical interventions may provide important severity adjustment 
information, minor (bedside) surgical procedures may be under-reported in hospital 
data. We explored a novel method to identify surgical interventions using culture 
descriptions. METHODS: We conducted an analysis (April 2005-March 2009) of the 
Health Facts® database (Cerner Corp., Kansas City, MO), containing comprehensive 
clinical records from 115 US hospitals. We included all adult initial admissions with 
ICD-9-CM codes speciﬁc to cSSSI and with eligible positive cultures (from pre-deﬁned 
skin/soft tissue sources or from blood) within the ﬁrst 48 hours. In addition to using 
ICD-9-CM codes to identify procedures, we identiﬁed surgical interventions as “pre-
sumed” when a culture was from a source/site that would require a procedure to 
obtain (e.g., abscess, aspirate, excision site). Because Staphylococcus aureus (SA) may 
present as an abscess, to explore the face validity of our method we stratiﬁed the 
results by SA status, and the SA further by methicillin resistance (MRSA) vs. sensitivity 
(MSSA). RESULTS: Among 7,183 patients included, 22.5% had a procedure identi-
ﬁed by ICD-9-CM code, 24.6% had a presumed procedure, and 36.6% were identiﬁed 
by both criteria. Overall, cultures were positive for MRSA in 33%, MSSA in 26% 
and non-SA organisms in 41%. When both procedure criteria were applied, surgical 
intervention among those with MRSA, MSSA and non-SA isolates was 34.9%, 21.4% 
and 19%, respectively. CONCLUSIONS: Our novel method appears feasible and may 
provide a more complete accounting of surgical procedures in cSSSI hospitalizations, 
though it requires clinical validation. Notably, in this large cohort of hospitalized cSSSI 
patients, nearly 60% had cultures positive for SA.
PIN48
USE OF AN ELECTRONIC HEALTH RECORD (EHR) DATABASE TO 
IDENTIFY HOSPITAL-ACQUIRED PNEUMONIA (HAP)
Campbell RS1, Spoeri RK1, Harris AD2, Kothari S3, Fiske S1, Hays HD1, Emons MF1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2University of Maryland, Baltimore, MD, USA, 
3Astellas Pharma US, Deerﬁeld, IL, USA
OBJECTIVES: HAP confers signiﬁcant mortality, morbidity and cost. Observational 
studies using real-world data have been limited. We sought to develop a methodology 
to identify and characterize patients with HAP in a large multihospital database 
without reliance upon radiographs or reviewer designation of infection origin. 
METHODS: We conducted a retrospective analysis (2005–2008) of the Health Facts® 
database (Cerner Corp., Kansas City, MO), which contains comprehensive clinical 
records from 115 US hospitals. Adult patients with a secondary discharge diagnosis 
consistent with pneumonia and a positive respiratory or blood culture obtained >48 
hours after admission were included as HAP. Respiratory cultures were deﬁned by 
site/source and the ﬁrst positive culture was selected. Qualiﬁed blood cultures were 
used when there was no respiratory culture and no other infection. Hierarchical selec-
tion was used when multiple cultures were collected at the same time. Methicillin-
resistant- (MRSA) or methicillin-sensitive- Staphylococcus aureus (MSSA) status was 
designated based on antibiotic susceptibilities. RESULTS: A total of 3,041 patients 
met criteria for HAP; 434 (14.3%) had an index culture positive for MRSA and 598 
(19.9%) for MSSA. Most patients (94%) qualiﬁed with a respiratory culture. The 
cohort was predominantly male (61%) and Caucasian (80%); mean age was 64 years. 
Primary diagnoses were varied; the three most common were other diseases of lung 
(9%), acute myocardial infarction (3.8%), and lung cancer (3.8%). MRSA patients 
were older, with more comorbidities vs MSSA patients. More MSSA isolates were 
polymicrobial (41%) vs. MRSA (22.5%) and included Gram-negative organisms 
(33% vs. 19%). Data generated is illustrative of methodology. CONCLUSIONS: Our 
algorithm identifying HAP patients within an EHR dataset potentially allows for 
larger sample size than other studies using clinical records from a single institution. 
Chart review is crucial to validate our approach and further work is needed to 
compare this deﬁnition with National Healthcare Safety Network deﬁnition.
PIN49
APPLICATION OF A NATIONAL PRESCRIPTION DATABASE TO DEVISE 
A PREDICTIVE MODEL FOR TAILORING HIV/AIDS THERAPEUTIC 
MANAGEMENT
Garavaglia SB1, Khalid M1, Bruno M2, Nichols LA1, Kagan SA3, Castle L1, Aubert RE1
1Medco Health Services, Inc, Franklin Lakes, NJ, USA, 2Pﬁzer Inc., New York, NY, USA, 
3Pﬁzer Inc., Atlanta, GA, USA
OBJECTIVES: Design a predictive model which determines the probability of patients 
using a drug typically prescribed later in the therapeutic management of HIV/AIDS. 
Determining when a patient may need to switch to a different antiretroviral regimen 
for HIV/AIDS due to complexities (e.g., resistance, poor adherence, etc.) remains 
challenging. Personalized approaches for the therapeutic management of HIV/AIDS 
are needed. A national database of pharmacy claims was analyzed to develop a predic-
tive model that can be used with traditional measures for regimen selection. 
METHODS: Beginning April 2006 to March 2009, prescription claim data for 15,828 
patients with continuous beneﬁt eligibility were analyzed for; antiretroviral drug 
regimen, presence of co-morbid illnesses (across 50 diseases), and basic demographics. 
Regimen identiﬁcation was based on drug combinations included in the 2008 DHHS 
Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adoles-
cents. Late-type regimens included enfuvirtide, etravirine, maraviroc, or raltegravir. A 
multivariate logistic regression model was utilized across drug-centric and patient-
centric domains to analyze the likelihood of a patient being prescribed a late-type 
regimen. RESULTS: N = 15,828 patients initially included in the model and n = 1,838 
(11.6%) identiﬁed with a claim for the target drug(s). Five or more drug regimens 
(OR = 32.81; CI: 28.29–38.04) and three or more average number of drugs per 
regimen (OR = 4.13; CI: 3.15 − 4.87) are the strongest predictors and dominate the 
model. Cancer (OR = 1.80; CI: 1.31–2.32), type 2 diabetes (OR = 1.74; CI: 1.38–
2.20), acne (OR = 1.56; CI: 1.09−2.22), and Benign Prostate Hyperplasia (OR = 1.54; 
CI: 1.14–2.08) were also signiﬁcant. CONCLUSIONS: Ability to develop and apply 
a highly predictive model identifying patients suitable for drugs typically prescribed 
later in therapeutic management of HIV/AIDS exists. Application of this model can 
lend signiﬁcant insight into patient management and further therapeutic precision. 
Additional studies are needed to conﬁrm the clinical beneﬁt of this model.
PIN50
METHODS TO IDENTIFY AND COMPARE BLOODSTREAM INFECTION 
RATES AMONG PATIENTS ADMINISTERED PARENTERAL NUTRITION 
VIA HOSPITAL COMPOUNDED VS. PREMIXED MULTI-CHAMBER BAGS
Liu FX1, Mercaldi K2, Reynolds MW3, Turpin R1
1Baxter Healthcare Corporation, Deerﬁeld, IL, USA, 2United BioSource Corporation, 
Bethesda, MD, USA, 3United BioSource Corporation, Lexington, MA, USA
BACKGROUND: Parenteral, or intravenous nutrition (PN) is used with patients when 
oral or enteral nutrition isn’t possible or adequate. Though PN provides important 
therapeutic beneﬁts, it also is associated with a higher risk of infection. Yet few studies 
have compared bloodstream infection rates (BSI) among patients receiving PN through 
custom compound formulations (COM) with standardized premixed multi-chamber 
bags (MCB). Our objective was to develop a credible approach to exploring the rela-
tionship between PN type and BSI rates. METHODS: We examined the Premier Per-
spectiveTM database for adult patients (≥18 years) who received PN between 2005 and 
2007. Patients were identiﬁed as either COM or MCB by searching standardized PN-
related charge codes. BSI rates were identiﬁed via ICD-9 codes; sensitivity analyses 
utilized ICD-9 codes plus ≥1 billing charge for iv antibiotics. Chi-square and t-tests 
compared differences between MCB and COM PN. Logistic regression modeled BSI 
rates controlling for patient and hospital characteristics, as well as risk factors for 
infection. Propensity score modeling was used to validate logistic regression ﬁndings. 
RESULTS: Of over 11 million inpatients in the database, 68,984 adult patients received 
PN and met study inclusion criteria. Of these, 4,669 received PN via MCB and 64,315 
received COM PN. Univariate statistics indicated that COM PN patients may have 
been at higher risk for infection. Controlling for observable variables, multivariate 
logistic regression indicated that MCBs were associated with a lower risk of BSI (31%), 
compared to COM (35%); p < 0.0001. In our sensitivity analysis, infection rates identi-
ﬁed via ICD-9 codes were similar to rates based on ICD-9 codes plus iv antibiotics. 
Propensity score modeling validated our logistic regression ﬁndings. CONCLUSIONS: 
A196 Abstracts
Large retrospective databases provide valuable information to examine adverse events 
associated with PN, which can be reliably identiﬁed and studied. Both sensitivity analy-
ses and model validation added credibility to our approach.
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
PRS1
A COMPARISON OF CLINICAL PROFILES, MEDICATION USE AND 
SYMPTOMOLOGY IN ASTHMA PATIENTS PRESCRIBED LOW/
MODERATE DOSE FLUTICASONE PROPIONATE/SALMETEROL OR 
MODERATE/HIGH DOSE FLUTICASONE PROPIONATE
Burke JP1, Stanford RH2, Polos PG3, Astry CL4, Riedel A1
1i3 Innovus, Eden Prairie, MN, USA, 2GlaxoSmithKline, Research Triangle Pk, NC, USA, 3i3 
Research, Basking Ridge, NJ, USA, 4i3 Research, Eden Prairie, MN, USA
OBJECTIVES: National asthma treatment guidelines recommend the use of low dose 
ICS plus a LABA or moderate to high dose ICS as the preferred treatment for moderate 
asthma. The purpose of this study was to determine if physicians prescribe low/moder-
ate dose ﬂuticasone propionate/salmeterol (FSC) or moderate/high dose ﬂuticasone 
propionate (FP) to subjects with similar asthma clinical proﬁles, medication use, and 
symptomology. METHODS: This was a retrospective observational study using 
medical, pharmacy, and enrollment information from a large, US managed care plan 
and linked medical chart data comparing 3 years of baseline characteristics and medi-
cation treatment patterns in adult asthma patients initiating FSC or FP. Data acquired 
from medical and pharmacy claims included provider specialty, baseline asthma medi-
cation resource use, occurrence of spirometry testing, and Deyo-Charlson co-morbid-
ity score. A random sample of medical charts (n = 460) was abstracted for baseline 
symptomology. RESULTS: A total of 32,189 subjects (average age: 46.6 [±14.4] years; 
64% female) with an asthma diagnosis and initiating FSC or FP were identiﬁed from 
1/1/06-12/31/07. Baseline co-morbidity scores were similar in FSC and FP patients 
(1.02 (1.31)) vs. 1.11 (1.50); p = 0.488). A greater proportion of patients receiving 
FSC had a baseline spirometry compared to FP patients (32.6% vs. 20.4%; p = 0.003) 
while. Shortness of breath was reported signiﬁcantly more often for FSC (48.7% in 
FSC vs 38.3% in FP; p = 0.024). Other asthma symptoms were reported a similar rate 
across both groups and no signiﬁcant differences in baseline use of other asthma 
medications were observed. CONCLUSIONS: Few signiﬁcant differences in either 
claims history or asthma symptomology were observed between patients prescribed 
low/moderate dose FSC or moderate/high dose FP for the ﬁrst time. Overall, physicians 
seem to be prescribing low/moderate dose FSC and moderate/high dose FP to similar 
asthma patients in alignment with national asthma treatment guidelines.
PRS2
A NOVEL METHODOLOGY FOR MEASURING THE INFLUENCE OF 
COMORBIDITY IN HEALTH OUTCOME STUDIES
Kiri VA1, MacKenzie G2
1PAREXEL International, Uxbridge, London, UK, 2University of Limerick, Limerick, Ireland
OBJECTIVES: In most studies, the inﬂuence of comorbidity is modelled additively as 
the number of comorbidities present or by an index (such as Charlson’s) chosen 
without regard to the outcome of interest. We question these approaches with a novel 
methodology noting that: outcome may not be associated linearly with comorbidity 
count, the weights combining a set of binary comorbidities need not be positive (i.e. 
hypothesis (B) that outcome worsens with increasing comorbidity may be false), and 
our ability to identify speciﬁc interactions inﬂuencing prognosis is lost METHODS: 
We analyzed a retrospective cohort of 3332 patients, aged 50+ in the UK General 
Practice Research Database diagnosed with COPD between 1990 and 1998, and with 
a ﬁrst COPD hospitalisation. Some 17 binary comorbidities were analysed in relation 
to risk of mortality and re-hospitalisation. We tested the null hypothesis (A), that 
comorbidity was similar in each layer of the two outcomes, crudely and adjusting for 
age and sex. Our methodology relies on logistic and log-linear modelling strategies 
for multidimensional contingency tables RESULTS: For both outcomes, hypothesis 
(A) was rejected (p < 0.001). Although comorbidity was found to inﬂuence death and 
rehospitalisation, the patterns of inﬂuence on the two outcomes were not similar and 
there were some with negative inﬂuence (i.e. comorbidities more frequent among 
survivors or those not rehospitalised); several signiﬁcant 2-way interactions were 
revealed. Whilst most signiﬁcant interactions were positive (especially for re-hospital-
isation) there was negative interaction for death (e.g. peripheral vascular disease and 
CVD were more frequent among survivors), thus rejecting hypothesis (B) CONCLU-
SIONS: The use of these modelling approaches, in addition to or in place of existing 
comorbidity indices, will improve our understanding of how comorbidity relates to 
disease natural history and outcomes of interest. The application of this method to 
understanding potential high risk patient strata in beneﬁt/risk management planning 
is particularly appealing
PRS3
THE PREVALENCE OF COMORBID CONDITIONS IN U.S. PATIENTS 
DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY  
DISEASE (COPD)
Hess G
SDI / Leonard Davis Inst University of Penn, Plymouth Meeting, PA, USA
OBJECTIVES: COPD is the 4th leading cause of death among U.S. adults. Retrospec-
tive observational studies, including outcomes research, can provide important com-
parative analyses to help identify optimal treatment patterns and therapies. However, 
such comparisons often require multivariate analysis, propensity score matching, a 
comorbidity index or other methods to adjust for differences in patient characteristics. 
Rates reported in clinical trials often vary signiﬁcantly from those observed in clinical 
practice. Using recent, real-world data this study was designed to identify the fre-
quency of diagnosed comorbid conditions in the COPD population and serve as a 
research reference for future comparative studies. METHODS: Private practitioner 
medical claims (CMS1500 records) from SDI Health’s data warehouse were extracted 
for the period November 1, 2007 to October 21, 2008. Patients were indexed to their 
ﬁrst observed COPD diagnosis during the study period. Qualifying patients had 2 or 
more claims for COPD; a valid age and gender; and were observed in the dataset for 
12 months or more from their index date. Patients could be diagnosed with COPD 
prior to the study period or new to the condition. Comorbid conditions of interest 
were deﬁned a priori. As possible, MEDRA codes used in clinical trials were cross-
walked to corresponding ICD-9 codes. All payer types were included. RESULTS: Of 
the 751,794 qualifying study patients, the mean age was 67.5 years (STD+/−13) and 
55.4% were female. The 1 year prevalence of comorbid conditions observed was: 
Supraventricular Arrhythmia13.2%, Atrial Fibrillation 9.7%, Depression 9.0%, 
Suicide 0.1%, Insomnia 4.1%, Ischemic disease (ATPC composite) 28.8%, Metabolic 
Syndrome 0.4%, and Other Mental Health conditions 14.7%. CONCLUSIONS: 
Patients with COPD have a variety of signiﬁcant comorbid conditions observed in 
real-world, clinical practice. These factors can affect ﬁndings of comparative studies 
and are important considerations for future research.
PRS4
ESTIMATION OF MORTALITY RISKS ATTRIBUTABLE TO COMORBIDITY 
IN COPD
Kiri VA
PAREXEL International, Uxbridge, London, UK
OBJECTIVES: Even in late-phase trials, it is common practice to exclude patients with 
certain pre-existing conditions based primarily on clinical knowledge. Such exclusions 
can result in low recruitment and associated consequences. Comorbidities are common 
in chronic diseases and for a speciﬁc outcome, data on the risk attributable to each 
can help inform decisions on inclusion/exclusion. We present a graphical methodology 
for obtaining such empirical evidence METHODS: A retrospective cohort of 23,881 
patients aged 50+ in the UK-GPRD at incident COPD diagnosis between 1990–1998 
provided our setting. Each death patient was matched to as many survivors from the 
same practice as possible, of same age, sex and COPD duration. Some 18 binary 
comorbidities measured at the time of death were analysed in relation to mortality. 
Using conditional logistic regression model, we estimated hazard ratio (HR) for each 
comorbidity, adjusted for key baseline characteristics as well as its prevalence at the 
time of COPD diagnosis (PRC) and in 1998 (PR98). We plotted the HRs against the 
PRCs and PR98s as graphs A and B respectively RESULTS: Some 2,938 dead patients 
were matched to 5792 survivors. The most contributors to mortality risk were- 
CHF (HR: 3.3 p < 0.0001; PRC = 15.6%, PR98 = 18.2%), lung cancer (HR: 20.4 
p < 0.0001; PRC = 0.7%, PR98 = 1.2%), other cancers (HR: 12.3 p < 0.0001; PRC 
= 0.7%, PR98 = 1.8%), and CVD (HR: 4.1 p < 0.0001; PRC = 3.2%, PR98 = 4.7%). 
Newly diagnosed moderate/severe liver disease (<1 year) was rare but with a high risk 
(HR: 16.7 p = 0.014; PRC = 0.3%, PR98 = 0.4%), suggesting such patients could be 
excluded in a trial. In contrast, diabetes-without-complication was common but with 
little effect on risk (HR: 1.2 p > 0.37; PRC = 5.1%, PR98 = 7.2%), suggesting such 
patients could be included in a trial with recruitment concerns CONCLUSIONS: The 
information provided by the tool can assist trial planning on sample size estimations 
as well as improve our understanding of how comorbidities inﬂuence outcome
PRS5
COMORBIDITIES, QUALITY OF LIFE, AND HEALTH CARE ACCESS BY 
RISK COHORT CHARACTERISTICS OF PEOPLE CALCULATED USING 
FRAMINGHAM RISK PERCENT FROM THE US NATIONAL HEALTH AND 
NUTRITION EXAMINATION SURVEY (NHANES)
Kim J, Nickman N
University of Utah, Salt Lake City, UT, USA
OBJECTIVES: To examine characteristics of demographic, clinical conditions, comor-
bidities, quality-of-life and health care access by risk cohorts calculated using Fram-
ingham risk percent in a United States (US) national sample. METHODS: 
Characteristics of 3 cohorts were deﬁned by Framingham low risk (<10%), middle 
risk (10%~20%) and high risk (>20%) and compared by mean and proportions of 
respondents using 2005–2006 National Health and Nutrition Examination Survey 
(NHNES) data. RESULTS: The sample comprised 1,751 persons aged ≥20 years with 
all necessary analysis variables (age, total cholesterol, smoking status, HDL, systolic 
blood pressure, and hypertension treatment) used to calculate Framingham 10-year 
risk percent. Compared to respondents in low and middle risk cohorts, the high risk 
cohort was older (61 years old vs. 42 and 60), more male (92% vs. 45% and 84%), 
and reported less years of education, less married (71% vs. 32% and 32%), more 
smokers (57% vs. 49% and 52%), higher levels of hypertension treatment (64% vs. 
19% and 51%) and a higher proportion of overweight and obese (76% vs. 61% and 
72%). More high risk cohort people reported diagnoses of hypertension (60% vs. 
24% and 45%), diabetes (15% vs. 5% and 11%), asthma (47% vs. 32% and 41%), 
and cancer (15% vs. 7% and 13%). Less of the high risk cohort reported “good 
health” conditions than those in low and middle risk cohorts (70% vs. 84% and 80%). 
The high risk cohort was more likely to report public insurance (54%) than either 
low (18%) or middle risk (46%) cohorts. CONCLUSIONS: An NHANES-based 
